STOCK TITAN

Immunic, Inc. - IMUX STOCK NEWS

Welcome to our dedicated page for Immunic news (Ticker: IMUX), a resource for investors and traders seeking the latest updates and insights on Immunic stock.

Immunic, Inc. (Nasdaq: IMUX) is a leading clinical-stage biopharmaceutical company focused on developing selective oral immunology therapies for chronic inflammatory and autoimmune diseases. With a dedicated pursuit of innovative solutions, Immunic is at the forefront of transforming therapeutic approaches for conditions such as relapsing-remitting multiple sclerosis, ulcerative colitis, Crohn's disease, and psoriasis.

The company’s flagship product, IMU-838, is a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme dihydroorotate dehydrogenase (DHODH). Currently in phase 2 and 3 clinical trials for various indications, IMU-838 has shown promising results in treating relapsing-remitting and progressive multiple sclerosis as well as moderate-to-severe ulcerative colitis. Additionally, IMU-838's mechanism as a nuclear receptor related 1 (Nurr1) activator underscores its potential neuroprotective effects.

Immunic is also advancing IMU-935, an inverse agonist of RORγt, and IMU-856, which aims to restore intestinal barrier function. IMU-856 is particularly notable for its innovative approach to gastrointestinal diseases, such as celiac disease and irritable bowel syndrome with diarrhea, by focusing on bowel architecture regeneration rather than immunomodulation.

Financially, Immunic has fortified its position with a significant private placement of up to $240 million, ensuring a strong cash runway through key clinical milestones. The company boasts robust partnerships with top-tier investors like BVF Partners and Janus Henderson Investors, reflecting strong market confidence in its clinical programs.

Highlighting its cutting-edge research, Immunic has presented pivotal data at prominent medical conferences, including the ACTRIMS Forum and has its results published in esteemed journals such as Neurology® Neuroimmunology & Neuroinflammation. These milestones not only solidify Immunic's scientific credibility but also mark significant progress in its clinical pipeline.

As of the latest updates, Immunic is gearing up for major clinical readouts, including the top-line data from the phase 2 CALLIPER trial expected in April 2025, and interim analyses from the phase 3 ENSURE trials anticipated in late 2024. The company’s achievements in these trials could potentially position vidofludimus calcium as a groundbreaking treatment option in the MS landscape.

Immunic continues to expand its patent portfolio, securing intellectual property rights that extend protection into the next two decades. This strategic move not only enhances its market exclusivity but also strengthens its competitive edge in the biotech industry.

Overall, Immunic, Inc. is poised for significant impact with its innovative oral therapies, backed by a strong financial foundation, strategic partnerships, and a commitment to addressing unmet medical needs in chronic inflammatory and autoimmune diseases.

Rhea-AI Summary
Biotech company Immunic, Inc. has received a Notice of Allowance from the USPTO for a patent application related to the treatment of Multiple Sclerosis with DHODH inhibitors.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.88%
Tags
none
-
Rhea-AI Summary
Biotech company Immunic, Inc. will present data from its phase 1b clinical trial of IMU-856, a small molecule modulator for celiac disease, at the AOECS conference. They will also attend BIO-Europe for partnering activities.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.92%
Tags
conferences
-
Rhea-AI Summary
Immunic announces positive results from phase 2 trial of vidofludimus calcium in ulcerative colitis
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.65%
Tags
Rhea-AI Summary
Immunic presents positive results from phase 1b clinical trial of IMU-856 for celiac disease at UEGW 2023
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary
Improvement in Serum Neurofilament Light Chain (NfL) Observed in Both Treatment Arms of Vidofludimus Calcium Over Placebo
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.92%
Tags
-
Rhea-AI Summary
Immunic announces positive interim data from phase 2 CALLIPER trial of vidofludimus calcium in patients with progressive multiple sclerosis (PMS)
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-13.84%
Tags
Rhea-AI Summary
Immunic, Inc. announces participation in scientific conferences in October.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.49%
Tags
conferences
-
Rhea-AI Summary
Immunic, Inc. to participate in industry and investor conferences in September
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.44%
Tags
conferences
-
Rhea-AI Summary
Immunic, Inc. has completed enrollment of its phase 2 CALLIPER trial of vidofludimus calcium in patients with progressive multiple sclerosis. The trial includes 467 patients and is focused on progressive forms of multiple sclerosis. An interim biomarker analysis is expected in the fall of 2023, and full data readout is expected in April 2025.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.03%
Tags
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.39%
Tags

FAQ

What is the current stock price of Immunic (IMUX)?

The current stock price of Immunic (IMUX) is $1 as of December 20, 2024.

What is the market cap of Immunic (IMUX)?

The market cap of Immunic (IMUX) is approximately 97.7M.

What is Immunic, Inc.'s primary focus?

Immunic, Inc. focuses on developing selective oral immunology therapies for chronic inflammatory and autoimmune diseases.

What are the key products of Immunic, Inc.?

Immunic's key products include IMU-838, a selective immune modulator, IMU-935, an inverse agonist of RORγt, and IMU-856, which targets intestinal barrier function restoration.

What stage are Immunic's clinical trials in?

Immunic's lead product, IMU-838, is in phase 2 and 3 clinical trials for various indications. IMU-856 is preparing for phase 2 clinical trials.

What diseases is Immunic aiming to treat with its therapies?

Immunic aims to treat diseases such as relapsing-remitting multiple sclerosis, ulcerative colitis, Crohn's disease, psoriasis, and celiac disease.

What financial achievements has Immunic recently made?

Immunic secured a private placement of up to $240 million, which ensures a strong financial position to advance its clinical programs.

What recent milestones have Immunic achieved?

Recent milestones include presenting data at the ACTRIMS Forum and publishing results in Neurology® Neuroimmunology & Neuroinflammation.

What is the significance of IMU-838?

IMU-838 inhibits DHODH, showing potential for treating multiple sclerosis and ulcerative colitis with neuroprotective and anti-inflammatory effects.

What potential does IMU-856 have?

IMU-856 aims to treat gastrointestinal diseases by restoring the intestinal barrier function, offering a novel approach beyond traditional immunomodulation.

How does Immunic protect its intellectual property?

Immunic has an extensive patent portfolio that provides protection for its product candidates into the next two decades.

Where can I find more information about Immunic, Inc.?

For more information, visit Immunic's official website at www.imux.com or the investor relations section at ir.imux.com.

Immunic, Inc.

Nasdaq:IMUX

IMUX Rankings

IMUX Stock Data

97.74M
89.15M
3.44%
64.85%
4.21%
Biotechnology
Pharmaceutical Preparations
Link
United States of America
NEW YORK